Revenue from Contracts with Customers (Tables)

6 Months Ended

Mar. 31, 2024

Revenue from Contract with Customer [Abstract]

Schedule of disaggregated revenue by significant business line

	Three months ended March 31,				Six months ended March 31,
	2024		2023		2024		2023
Significant Business Line
Multiomics	$	62,218	$	62,236	$	124,938	$	123,326
Core Products (1)		44,844		43,738		93,730		91,576
Sample Repository Solutions		29,293		27,305		59,412		54,921
B Medical Systems		22,779		15,122		35,371		56,944
Total revenue	$	159,134	$	148,401	$	313,451	$	326,767

(1) Core Products are Automated Stores, Cryogenic Systems, Automated Sample Tube, and Consumables and Instruments.

Schedule of remaining performance obligations

	As of March 31, 2024
	Less than 1 Year		Greater than 1 Year		Total
Remaining performance obligations	$	94,719	$	27,379	$	122,098